Medical Condition News

RSS

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say.

25 Feb 2010

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

The new Jefferson Vascular Center at Thomas Jefferson University Hospital offers an integrated, multidisciplinary approach to the diagnosis, management and treatment of vascular diseases (diseases of blood vessels) and thrombotic (blood-clotting) disorders all under one roof.

25 Feb 2010

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

Researchers from the Toronto Western Research Institute noted a higher prevalence of arthritis and arthritis-attributable activity limitations (AAL) in the U.S. versus the Canadian population. The authors attribute the higher prevalence of arthritis and AAL to a greater level of obesity and physical inactivity in Americans, particularly women.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

End-stage ankle arthritis: New treatment options for baby boomers

There's good news for active older adults who are plagued with arthritic ankles. Surgeons presenting today at the American College of Foot and Ankle Surgeons' Annual Scientific Conference in Las Vegas are re-thinking treatment approaches for end-stage ankle arthritis.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Nearly four in 10 transient ischemic attack (TIA) and minor ischemic stroke patients may experience mental impairment, according to a study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Single or unhappily married men may have an elevated risk of fatal stroke in the coming decades, according to a large study presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Genetic Disorder Tracker introduced by Guidepoint Global

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.

25 Feb 2010

More young people are having strokes while older people are having fewer: Study

More young people are having strokes while older people are having fewer, according to data from Ohio and Kentucky presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Researchers develop evaluation tool to help guide asymptomatic pancreatic cyst treatment

As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.

25 Feb 2010

Researchers to test Radio-embolisation technique in patients with bowel cancer

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.

24 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

InfraReDx, Inc., an innovative medical device company focused on developing novel diagnostic imaging technologies to accurately identify and characterize diseased intracoronary tissues, today announced that the Company will be exhibiting at LUMEN 2010, the world's premier ST-elevation myocardial infarction (STEMI) meeting, to be held February 25-27, 2010 at the Loews Miami Beach Hotel in Miami Beach, Florida. The 9th Annual LUMEN meeting is an educational symposium providing updates from world-renowned experts in key areas of interventional cardiology and vascular intervention.

24 Feb 2010

Meditation improves cognition in people with memory loss

The Alzheimer's Research and Prevention Foundation today announced data demonstrating that a specific meditation performed daily for eight weeks increased brain activity in areas central to memory and actually improved cognition in patients suffering from memory problems. The results of the study, conducted at the University of Pennsylvania, were published in an early online version of an article scheduled to appear in the Journal of Alzheimer's Disease (Volume 20:2, April 2010).

24 Feb 2010

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Arena Pharmaceuticals, Inc. announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the US Food and Drug Administration (FDA). Arena submitted the lorcaserin NDA on December 22, 2009, and expects to learn the Prescription Drug User Fee Act (PDUFA) date in the next few weeks. The PDUFA date is the target date for the FDA to complete its review of an NDA.

24 Feb 2010

Shire receives FDA Fast Track designation for REPLAGAL

Shire plc, the global specialty biopharmaceutical company, announces it has received Fast Track designation from the FDA for REPLAGAL(R) (agalsidase alfa), its enzyme replacement therapy for Fabry disease.

24 Feb 2010

Medical Condition News

High blood pressure drugs may be useful in preventing and treating diabetic retinopathy: Study

JVC offers treatment for vascular diseases and thrombotic disorders under one roof

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

EpiCept provides business update and fourth-quarter financial highlights

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

End-stage ankle arthritis: New treatment options for baby boomers

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Study: Single, unhappily married men may have elevated risk of fatal stroke in the coming decades

Genetic Disorder Tracker introduced by Guidepoint Global

More young people are having strokes while older people are having fewer: Study

Researchers develop evaluation tool to help guide asymptomatic pancreatic cyst treatment

Researchers to test Radio-embolisation technique in patients with bowel cancer

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

InfraReDx to exhibit novel LipiScan Coronary Imaging System at LUMEN 2010

Meditation improves cognition in people with memory loss

FDA accepts Arena Pharmaceuticals' lorcaserin NDA

Shire receives FDA Fast Track designation for REPLAGAL

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News